<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209949</url>
  </required_header>
  <id_info>
    <org_study_id>US10179</org_study_id>
    <nct_id>NCT01209949</nct_id>
  </id_info>
  <brief_title>Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris</brief_title>
  <official_title>Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat
      mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and
      video diaries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants who were a Success (Subject's Global Assessment of 'Clear or 'Almost Clear') at week 12. Subject's Global Assessment is measured on a scale (Clear, Almost Clear, Mild, Moderate, Severe, Very Severe) with Clear being best and Very Severe being worst.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>Mean percent change from baseline in lesions counts (inflammatory, non-inflammatory, and total) at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tolerability Assessments Resulting in an Adverse Event</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants with tolerability assessments resulting in an adverse event. Tolerability assessments include erythema (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Scaling (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Dryness (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Stinging/Burning (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with a score of None being best and a score of Severe being worst.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel</intervention_name>
    <description>Apply adapalene BPO gel once daily in the evening for 12 weeks</description>
    <arm_group_label>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel</arm_group_label>
    <other_name>EpiduoÂ® Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, aged 16 to 25 years inclusive;

          -  Subjects with mild or moderate facial acne (Investigator's Global Assessment (IGA) = 2
             or 3;

          -  A minimum of 10 inflammatory lesions (papules and pustules) on the face (excluding the
             nose);

          -  Subjects who agree to be photographed at each visit;

          -  Subjects who agree to be video recorded by study designated staff members. They should
             be able to clearly and comfortably communicate their responses to questions and
             express their thoughts related to their disease and treatment throughout the study

        Exclusion Criteria:

          -  Subjects with nodules, cysts, acne conglobata, acne fulminans, secondary acne
             (chloracne, drug-induced acne, etc.) or severe acne requiring systemic treatment;

          -  Subjects with a wash-out period for topical acne treatment on the face less than 30
             days

          -  Subjects with a wash-out period for systemic acne treatment less than 30 days with the
             exception of isotretinoin which requires a washout of 4 months;

          -  Subjects who are currently being treated with antibiotics;

          -  Subjects who foresee intensive ultraviolet (UV) exposure during the study (mountain
             sports, UV radiation, sunbathing, tanning beds, etc.);

          -  Subjects who refuse photographic and videography procedures and/or refuse to sign a
             full release for their use in promotional materials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald W Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, L.P.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas J. Stephens and Associates</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <results_first_submitted>December 13, 2011</results_first_submitted>
  <results_first_submitted_qc>January 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2012</results_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment period: First subject was enrolled on October 7, 2010 and the last subject was enrolled on October 12, 2010.
Types of location: Investigative site was located at a research center.</recruitment_details>
      <pre_assignment_details>Wash-out period up to baseline was 30 days for topical and systemic acne treatments with the exception of isotretinoin, which had a wash-out period of 4 months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adapalene 0.1% and Benzoyl Peroxide 2.5% Gel</title>
          <description>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel - apply topically to the face once daily in the evening for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adapalene 0.1% and Benzoyl Peroxide 2.5% Gel</title>
          <description>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel - apply topically to the face once daily in the evening for 12 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.5" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12</title>
        <description>Number of participants who were a Success (Subject's Global Assessment of 'Clear or 'Almost Clear') at week 12. Subject's Global Assessment is measured on a scale (Clear, Almost Clear, Mild, Moderate, Severe, Very Severe) with Clear being best and Very Severe being worst.</description>
        <time_frame>12 weeks</time_frame>
        <population>Modified ITT (subjects with a baseline and week 12 visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene 0.1% and Benzoyl Peroxide 2.5% Gel</title>
            <description>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel - apply topically to the face once daily in the evening for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12</title>
          <description>Number of participants who were a Success (Subject's Global Assessment of 'Clear or 'Almost Clear') at week 12. Subject's Global Assessment is measured on a scale (Clear, Almost Clear, Mild, Moderate, Severe, Very Severe) with Clear being best and Very Severe being worst.</description>
          <population>Modified ITT (subjects with a baseline and week 12 visit)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12.</title>
        <description>Mean percent change from baseline in lesions counts (inflammatory, non-inflammatory, and total) at week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>Modified ITT (subjects with a baseline and week 12 visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene 0.1% and Benzoyl Peroxide 2.5% Gel</title>
            <description>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel - apply topically to the face once daily in the evening for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12.</title>
          <description>Mean percent change from baseline in lesions counts (inflammatory, non-inflammatory, and total) at week 12.</description>
          <population>Modified ITT (subjects with a baseline and week 12 visit)</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammatory Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.1" spread="34.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noninflammatory Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.1" spread="19.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.7" spread="24.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tolerability Assessments Resulting in an Adverse Event</title>
        <description>Number of participants with tolerability assessments resulting in an adverse event. Tolerability assessments include erythema (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Scaling (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Dryness (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Stinging/Burning (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with a score of None being best and a score of Severe being worst.</description>
        <time_frame>12 weeks</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene 0.1% and Benzoyl Peroxide 2.5% Gel</title>
            <description>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel - apply topically to the face once daily in the evening for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tolerability Assessments Resulting in an Adverse Event</title>
          <description>Number of participants with tolerability assessments resulting in an adverse event. Tolerability assessments include erythema (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Scaling (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Dryness (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe); Stinging/Burning (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with a score of None being best and a score of Severe being worst.</description>
          <population>Safety</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adapalene 0.1% and Benzoyl Peroxide 2.5% Gel</title>
          <description>Adapalene 0.1% and Benzoyl Peroxide 2.5% gel - apply topically to the face once daily in the evening for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Norman Preston</name_or_title>
      <organization>Galderma Laboratories, L.P.</organization>
      <phone>817-961-5360</phone>
      <email>Norman.Preston@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

